MannKind Corporation Participating at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming conferences where CEO Michael Castagna will speak.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming conferences where CEO Michael Castagna will speak. Key events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 3:30 pm EDT, the Cantor Global Virtual Healthcare Conference on September 15 at 8:40 am EDT, and the Oppenheimer Fall Healthcare Summit on September 21 at 10:50 am EDT. The presentations will be accessible through a live webcast on the company's website, with replays available for 14 days.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was -0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.
- H.C. Wainwright 22nd Annual Global Investment Conference - Fireside Chat on Monday, September 14, 2020 at 3:30 pm (EDT)
- 2020 Cantor Global Virtual Healthcare Conference - Fireside Chat on Tuesday, September 15, 2020 at 8:40 am - 9:10 am (EDT)
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Fireside Chat on Monday, September 21, 2020 at 10:50 am - 11:30 am (EDT)
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
818-661-5000
ir@mannkindcorp.com
Source: MannKind Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.